Biogen (Portugal)

Homepage: biogen.pt

Parent institution: Biogen (United States)

ROR: 057mkdb21

OpenAlex ID: I4405257407

TyPed study: Natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal

2021 · Filipe Palavra, Sónia Figueiroa, et al. · Multiple Sclerosis and Related Disorders · 22

JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results

2019 · Maria José Sá, Carla Cecília Nunes, et al. · Journal of the Neurological Sciences · 8

Cost-Utility Analysis of Delayed-Release Dimethyl Fumerate For The Treatment of Relapsing-Remitting Multiple Sclerosis In Portugal

2015 · L Silva Miguel, J de Sá, et al. · Value in Health · 3

IMPRESS: Impact of Baseline Depression in Multiple Sclerosis Patients Starting Treatment with Interferon β-1a

2023 · António Salgado, Ângela Silva, et al. · Sinapse

Works count: 4

Citation count: 55